At the news
? BEARISHIMPACT 6/10 S-3 filed Jul 2, 2026 at 16:02 ET
Inovio Pharmaceuticals (INO) filed a universal shelf registration statement on Form S-3 on July 2, 2026, to raise up to $300,000,000 from the sale of common stock, preferred stock, debt securities, and/or warrants over time. This follows a pattern of frequent capital raises (at least four underwritten offerings in the prior 18 months through March 2026 per the 10-Q) and comes as the company awaits an October 30, 2026 PDUFA date for its lead BLA candidate INO-3107. The filing signals ongoing and substantial dilution for existing shareholders, funding development and working capital needs at a sub-$100M market cap.
- Shelf registration allows for up to $300,000,000 in aggregate offerings of common stock, preferred stock, debt securities, and warrants.
- Common stock closed at $1.19/share on July 1, 2026, with a market cap of approximately $98M.
- The company has a history of dilutive financing: the 10-Q for Q1 2026 discloses at least five capital raises (December 2024, April 2025, July 2025, November 2025, April 2026) in the prior 18 months using common stock and warrants.
- As of March 31, 2026, the company had $33.9M in cash and equivalents and no product revenue.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access